Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS) (LUCAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04228237
Recruitment Status : Recruiting
First Posted : January 14, 2020
Last Update Posted : March 9, 2022
Sponsor:
Collaborator:
OAKS Consulting s.r.o.
Information provided by (Responsible Party):
Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Condition or disease
Lung Cancer

Detailed Description:

Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most other oncological diseases, a complex multidisciplinary process. Due to the lack of information on the speed and success of the initial diagnosis, the use of the necessary laboratory techniques, and the individual therapeutic steps leading to cure or medical failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out long-term non-interventional monitoring of newly diagnosed patients.

This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures will be used according to the decision of the physician. All patients with bronchogenic carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS)
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : May 31, 2025
Estimated Study Completion Date : May 31, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 60 months of follow-up ]
    Time from randomization until death from any cause

  2. Progression-free survival (PFS) [ Time Frame: any treatment during 60 months of follow-up ]
    Time from randomization until disease progression or death

  3. Time to treatment discontinuation (TTD) [ Time Frame: any treatment during 60 months of follow-up ]
    time from starting a medication until treatment discontinuation or death


Secondary Outcome Measures :
  1. Time to next treatment (TTNT) [ Time Frame: 60 months of follow-up ]
    Time from end of primary treatment to institution of next therapy


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
all newly diagnosed patients in participating pulmonology centers
Criteria

Inclusion Criteria:

- clinical diagnosis of lung cancer (C34 in MKN classification)

Exclusion Criteria:

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04228237


Contacts
Layout table for location contacts
Contact: Jana Alahakoon +420602350988 jana.alahakoon@oaks.cz
Contact: Jaroslav Duba +420606613224 jaroslav.duba@oaks.cz

Locations
Layout table for location information
Czechia
University hospital Brno Recruiting
Brno, Czechia, 62500
Contact: Jana Skrickova, Prof.    +420602726490    skrickova.jana@fnbrno.cz   
University hospital Hradec Kralove Recruiting
Hradec Kralove, Czechia, 50005
Contact: Vladimir Koblizek, Ass.Prof.    +420495834772    vladimir.koblizek@fnhk.cz   
University hospital Olomouc Recruiting
Olomouc, Czechia, 77900
Contact: Petr Jakubec, Prof.    +420588443560    petr.jakubec@fnol.cz   
University hospital Plzen Recruiting
Plzen, Czechia, 30599
Contact: Martin Svaton, Ass. Prof.    +420377402238    svatonm@fnplzen.cz   
University Thomayer hospital Recruiting
Prague, Czechia, 140 59
Contact: Martina Koziar Vasakova, Prof.    +420261082372    martina.koziarvasakova@ftn.cz   
University hospital Motol Recruiting
Praha 5, Czechia, 15006
Contact: Miloslav Marel, Prof.    +420224436659    miloslav.marel@fnmotol.cz   
University hospital Bulovka Recruiting
Praha 8, Česká Republika, Czechia, 18000
Contact: Petr Opalka, MD    +420266082267    petr.opalka@bulovka.cz   
Sponsors and Collaborators
Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.
OAKS Consulting s.r.o.
Investigators
Layout table for investigator information
Principal Investigator: Martina Koziar Vasakova, Prof. University Thomayer hospital Prague
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.
ClinicalTrials.gov Identifier: NCT04228237    
Other Study ID Numbers: CPFS/Reg18.01
First Posted: January 14, 2020    Key Record Dates
Last Update Posted: March 9, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.:
lung cancer
bronchogenic carcinoma
diagnosis
treatment
non-interventional
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Lung Neoplasms
Carcinoma, Bronchogenic
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
 Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Bronchial Neoplasms